986例老年住院患者使用灯盏细辛注射液的安全性评价  

Safety evaluation of Dengzhanxixin injection in 986 elderly inpatients

作　　者：纪立伟[1] 周冰[2] 张亚同[1] 张俊[2] 林鑫[3] 倪倩[1] 胡欣[1] 孙春华[1] 

机构地区：[1]卫生部北京医院药学部,100730 [2]北京市药品评价中心 [3]北京大学公共卫生学院流行病与统计学系

出　　处：《中华老年医学杂志》2009年第9期715-718,共4页Chinese Journal of Geriatrics

基　　金：北京市药品监督管理局局级课题（BJADR200601）

摘　　要：目的评价老年患者使用灯盏细辛注射液的安全性。方法调查986例使用灯盏细辛注射液住院患者（男620例，女366例）的病历资料，填写调查表。调查表项目包括年龄、性别、出院诊断、症状、用药剂量及疗程、实验室检查、药品不良反应情况及药品对患者原患疾病的影响。结果患者平均年龄（74．3±7．5）岁，使用灯盏细辛注射液的平均剂量为（38．2±4．4）ml，平均疗程为（10．8±5．2）d，静脉滴注，1次／d。有8例患者出现不良反应，总不良反应发生率为0．81％。用药前后，除血红蛋白及血糖外（t值或口值分别为1226．5，2620．0，均P〈O．05），丙氨酸转氨酶、天冬氨酸转氨酶、肌酐、尿素氮、白细胞计数的变化差异无统计学意义（t值或口值分别为122．5、405．0、513。5、996．5、956．5，均P〉0．05）。结论老年患者按说明书推荐方法使用灯盏细辛注射液较安全。Objective To investigate the rationality and safety of dengzhanxixin injection used in elderly inpatients. Methods The clinical data of 986 inpatients including 620 males and 366 females were collected, and questionnaires containing age, sex, discharge diagnosis, symptoms, drug dosage, course of treatment, laboratory examination, adverse drug reaction and drug effect were analyzed. Results For the 986 cases, the average age was（74.3±7.5）years. The average dose of dengzhanxixin injection was （38.2±4.4） ml, once daily by intravenous drip, and the average period of treatment was （10.8±5.2） days. The adverse reaction rate was 0.81%. The levels of blood glucose and hemoglobin were decreased after treatment（t or μ=1226.5,2620.0, both P〈0.05）, but there were no statistical differences in the levels of alanine aminotransferase （ALT）, aspartate aminotransferase （AST）, creatinine （CREA）, blood urea nitrogen （BUN） and white blood cell count （WBC） before and after treatment （t or μ=122.5, 405.0, 513. 5, 996.5, 956.5, all P〈0.05）. Conclusions It is safe to use dengzhanxixin injection according to the medication description for elderly inpatients.

关 键 词：灯盏细辛 药品评价 

分 类 号：R686[医药卫生—骨科学]